ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
The immunobiology of myeloid-derived suppressor cells in cancer.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05615883 (Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients), which is not on this map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- ERO1α as a Potential Drug Target for Breast Cancer: A Systematic Review of Current Evidence.International journal of molecular sciences · 2025Pooled it
- β-Ionone inhibits A. sydowii mediated LUAD progression by inhibiting myeloid-derived suppressor cell (MDSC) expansion and activation.Journal of molecular histology · 2026Article
- B7-H3 (CD276) regulates myeloid-derived suppressor cell differentiation in pulmonary fibrosis.Frontiers in immunology · 2026Article
- A novel method for isolation of tumor infiltrating myeloid-derived suppressor cells from human lung tumor tissue.Scientific reports · 2025Article
- Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2023Review
- A novel proteomic-based model for predicting colorectal cancer with Schistosoma japonicum co-infection by integrated bioinformatics analysis and machine learning.BMC medical genomics · 2023Article
- Somatic Mutations Alter Interleukin Signaling Pathways in Grade II Invasive Breast Cancer Patients: An Egyptian Experience.Current issues in molecular biology · 2022Article
- Disseminated carcinomatosis of the bone marrow caused by granulocyte colony-stimulating factor: A case report and review of literature.World journal of gastrointestinal oncology · 2022Article
- The expression of VISTA on CD4+ T cells associate with poor prognosis and immune status in non-small cell lung cancer patients.Bosnian journal of basic medical sciences · 2022Article
- Post-Transplant Cyclophosphamide after Matched Sibling and Unrelated Donor Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia.International journal of molecular sciences · 2022Article
- Role of T Regulatory Cells and Myeloid-Derived Suppressor Cells in COVID-19.Journal of immunology research · 2022Review
- B7H3-dependent myeloid-derived suppressor cell recruitment and activation in pulmonary fibrosis.Frontiers in immunology · 2022Article
- Tumor immunomodulatory effects of polyphenols.Frontiers in immunology · 2022Review
- Bioinformatics and systems biology approaches to identify molecular targeting mechanism influenced by COVID-19 on heart failure.Frontiers in immunology · 2022Article
- Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets.Exploration of targeted anti-tumor therapy · 2022Review
- Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.Frontiers in immunology · 2022Review
- Role of myeloid-derived suppressor cells in viral respiratory infections; Hints for discovering therapeutic targets for COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- PD-L1 Expression in Different Segments and Histological Types of Ovarian Cancer According to Lymphocytic Infiltrate.Medicina (Kaunas, Lithuania) · 2021Article
- The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer.Journal of personalized medicine · 2021Review
- Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice.Journal for immunotherapy of cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment is a complex and heterogeneous milieu in which multiple interactions occur between tumor and host cells. Immunosuppressive cells which are present in this microenvironment, such as regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs), play an important role in tumor progression, via down-regulation of antitumor responses. MDSCs represent a heterogeneous group of cells originated from the myeloid lineage that are in the immature state. These cells markedly accumulate under pathologic conditions, such as cancer, infection, and inflammation, and use various mechanisms to inhibit both adaptive and innate immune responses. These immunosuppressive mechanisms include deprivation of T cells from essential amino acids, induction of oxidative stress, interference with viability and trafficking of T cells, induction of immunosuppressive cells, and finally polarizing immunity toward a tumor-promoting type 2 phenotype. In addition to suppression of antitumor immune responses, MDSCs can also enhance the tumor metastasis and angiogenesis. Previous studies have shown that increased frequency of MDSCs is related to the tumor progression. Moreover, various drugs that directly target these cells or reverse their suppressive activity can improve antitumor immune responses as well as increase the efficacy of immunotherapeutic intervention. In this review, we will first discuss on the immunobiology of MDSCs in an attempt to find the role of these cells in tumor progression and then discuss about therapeutic approaches to target these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.